Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Other Non Operating Income: 2020-2025

Historic Other Non Operating Income for Whitehawk Therapeutics (WHWK) over the last 5 years, with Sep 2025 value amounting to $1.8 million.

  • Whitehawk Therapeutics' Other Non Operating Income rose 107.61% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.8 million, marking a year-over-year increase of 1946.83%. This contributed to the annual value of $3.8 million for FY2024, which is 38.93% down from last year.
  • Per Whitehawk Therapeutics' latest filing, its Other Non Operating Income stood at $1.8 million for Q3 2025, which was down 15.65% from $2.1 million recorded in Q2 2025.
  • Over the past 5 years, Whitehawk Therapeutics' Other Non Operating Income peaked at $88.2 million during Q1 2025, and registered a low of -$1.4 million during Q1 2021.
  • Moreover, its 3-year median value for Other Non Operating Income was $1.5 million (2023), whereas its average is $9.3 million.
  • As far as peak fluctuations go, Whitehawk Therapeutics' Other Non Operating Income crashed by 95.73% in 2022, and later soared by 7,114.55% in 2025.
  • Whitehawk Therapeutics' Other Non Operating Income (Quarterly) stood at -$45,000 in 2021, then skyrocketed by 3,544.44% to $1.6 million in 2022, then decreased by 6.77% to $1.4 million in 2023, then tumbled by 53.22% to $676,000 in 2024, then surged by 107.61% to $1.8 million in 2025.
  • Its Other Non Operating Income was $1.8 million in Q3 2025, compared to $2.1 million in Q2 2025 and $88.2 million in Q1 2025.